SEC Comment Letter 0000000000-24-002044 to C3is Inc. (CISS) (CIK 0001951067) (CISS)
C3is Inc. (CISS) (CIK 0001951067)
Date: Feb. 22, 2024 · CIK: 0001951067 · Accession: 0000000000-24-002044
AI Filing Summary & Sentiment
File numbers found in text: 333-276868
Letter
United States securities and exchange commission logo February 22, 2024 Dr. Diamantis Andriotis Chief Executive Officer C3is Inc. 331 Kifissias Avenue Erithrea 14561 Athens, Greece Re:C3is Inc. Registration Statement on Form F-1 Filed February 5, 2024 File No. 333-276868 Dear Dr. Diamantis Andriotis: We have conducted a limited review of your registration statement and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Registration Statement on Form F-1 Risk Factors Risks Related to our Common Shares, page 52 1.We note your disclosure on page 54 that you received notice that you were not in compliance with Nasdaq Listing Rule 5550(a)(2) and in order to regain compliance, would need to maintain a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading days prior to February 20, 2024. Please update your disclosure to describe your discussions with Nasdaq and clarify whether you were able to satisfy the compliance minimums. If you were not, please disclose the next steps you intend to take in order to meet applicable listing requirements. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
FirstName LastNameDr. Diamantis Andriotis Comapany NameC3is Inc. February 22, 2024 Page 2 FirstName LastName Dr. Diamantis Andriotis C3is Inc. February 22, 2024 Page 2 Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. Please contact Michael Purcell at 202-551-5351 or Daniel Morris at 202-551-3314 with any questions. Sincerely, Division of Corporation Finance Office of Energy & Transportation cc: Finn Murphy
Show Raw Text
United States securities and exchange commission logo
February 22, 2024
Dr. Diamantis Andriotis
Chief Executive Officer
C3is Inc.
331 Kifissias Avenue Erithrea
14561 Athens, Greece
Re:C3is Inc.
Registration Statement on Form F-1
Filed February 5, 2024
File No. 333-276868
Dear Dr. Diamantis Andriotis:
We have conducted a limited review of your registration statement and have the
following comment.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe a comment applies to your facts and circumstances
or do not believe an amendment is appropriate, please tell us why in your response.
After reviewing any amendment to your registration statement and the information you
provide in response to this letter, we may have additional comments.
Registration Statement on Form F-1
Risk Factors
Risks Related to our Common Shares, page 52
1.We note your disclosure on page 54 that you received notice that you were not in
compliance with Nasdaq Listing Rule 5550(a)(2) and in order to regain compliance,
would need to maintain a minimum closing bid price of at least $1.00 per share for a
minimum of 10 consecutive trading days prior to February 20, 2024. Please update your
disclosure to describe your discussions with Nasdaq and clarify whether you were able to
satisfy the compliance minimums. If you were not, please disclose the next steps you
intend to take in order to meet applicable listing requirements.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
FirstName LastNameDr. Diamantis Andriotis
Comapany NameC3is Inc.
February 22, 2024 Page 2
FirstName LastName
Dr. Diamantis Andriotis
C3is Inc.
February 22, 2024
Page 2
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
Please contact Michael Purcell at 202-551-5351 or Daniel Morris at 202-551-3314 with
any questions.
Sincerely,
Division of Corporation Finance
Office of Energy & Transportation
cc: Finn Murphy